文献速递病毒性肝炎

乙型肝炎病毒RNA作为安全停用抗病毒药物的生物标志物:核苷(酸)类似物停药的前瞻性研究

Hepatitis B Virus RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal.
PubMed 文献 · J Infect Dis · 2025-01-01

乙型肝炎研究网络免疫活动试验前瞻性评估了富马酸替诺福韦二吡呋酯(TDF)治疗192周±聚乙二醇干扰素α-2a初始24周后按方案停药,93例停药者中55.9%治疗结束时HBV RNA不可定量,28.3%获得持续部分治愈;治疗结束时HBV RNA可定量者持续部分治愈可能性仅3%,而HBV RNA不可定量且定量HBsAg<100 IU/mL者为73%。

要点

  • 停药后48周内33.3%出现ALT flares>5倍正常上限,治疗前年龄≥35岁和治疗结束时HBV RNA可定量是最佳预测因素。
  • 治疗结束时HBV RNA不可定量和定量HBsAg<100 IU/mL是持续部分治愈的最佳预测因素。
  • HBV RNA可定量者持续部分治愈可能性仅3%,而HBV RNA不可定量且定量HBsAg<100 IU/mL者为73%。

核心结论

  • HBV RNA是预测获得持续部分治愈可能性和安全停用核苷(酸)类似物的有用生物标志物。

研究设计与样本

  • 乙型肝炎研究网络免疫活动试验(ClinicalTrials.gov NCT01369212)前瞻性评估富马酸替诺福韦二吡呋酯(TDF)治疗192周±聚乙二醇干扰素α-2a初始24周,随后在合格参与者中按方案停用TDF。
  • 93例停用TDF的参与者中,52例接受TDF+聚乙二醇干扰素α-2a,41例接受TDF单药治疗。
  • 评估HBV RNA作为停用TDF后48周时ALT flares和持续部分治愈(HBV DNA<2000 IU/mL)的预测因素。

主要发现

  • 93例停用TDF的参与者中,52例(55.9%)在治疗结束时HBV RNA不可定量。
  • 停用治疗48周时,33.3%出现ALT flares>5倍正常上限。
  • 26例(28.3%)获得持续部分治愈,其中3例(11.5%)伴有ALT flare。
  • 治疗前年龄≥35岁和治疗结束时HBV RNA可定量是ALT flares>5倍正常上限的最佳预测因素(训练集和测试集AUC分别为0.74和0.85)。
  • 治疗结束时HBV RNA不可定量和定量HBsAg<100 IU/mL是持续部分治愈的最佳预测因素(训练集和测试集AUC分别为0.84和0.93)。

关键数值与推荐

  • 若治疗结束时HBV RNA可定量,持续部分治愈的可能性仅为3%。
  • 若治疗结束时HBV RNA不可定量且定量HBsAg<100 IU/mL,持续部分治愈的可能性为73%。
  • 持续部分治愈定义为停用治疗48周时HBV DNA<2000 IU/mL且ALT正常(男性≤30 U/L,女性≤20 U/L)。

临床怎么用

  • HBV RNA是预测获得持续部分治愈可能性和安全停用核苷(酸)类似物的有用生物标志物。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Withdrawal of nucleos(t)ide analogue therapy is associated with hepatitis B surface antigen (HBsAg) loss and sustained off-therapy partial cure (normal alanine aminotransferase [ALT] ≤30 U/L for males and ≤20 U/L for females with hepatitis B virus [HBV] DNA <2000 IU/mL) but should be offered only to those most likely to benefit. HBV RNA may be useful for risk stratification. METHODS: The Hepatitis B Research Network Immune-Active Trial prospectively evaluated treatment with tenofovir disoproxil fumarate (TDF) for 192 weeks ± peginterferon alfa-2a for the initial 24 weeks, followed by protocolized withdrawal of TDF among eligible participants (ClinicalTrials.gov NCT01369212). HBV RNA was evaluated as a predictor of ALT flares and sustained partial cure (HBV DNA <2000 IU/mL) 48 weeks after TDF withdrawal. RESULTS: Of 93 participants discontinuing TDF (n = 52, TDF + peginterferon alfa-2a; n = 41, TDF alone), 52 (55.9%) had unquantifiable HBV RNA at end of treatment. ALT flares >5 times the upper limit of normal at 48 weeks off therapy occurred in 33.3%, with pretreatment age (≥35 years) and quantifiable HBV RNA at end of treatment the best predictors (area under the receiver operating characteristic curves, 0.74 and 0.85 for training and test sets, respectively). A total of 26 (28.3%) had sustained partial cure, 3 (11.5%) with ALT flare. Nonquantifiable HBV RNA and quantitative HBsAg <100 IU/mL at end of treatment were the best predictors of sustained partial cure (area under the receiver operating characteristic curves, 0.84 and 0.93 for training and test sets). If HBV RNA was quantifiable at end of treatment, the likelihood of sustained partial cure was only 3%, whereas if HBV RNA was unquantifiable and quantitative HBsAg was <100 IU/mL, this likelihood was 73%. CONCLUSIONS: HBV RNA is a useful biomarker in predicting likelihood of achieving sustained partial cure and safe withdrawal of nucleos(t)ide analogues.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Terrault NA, Sterling R, Lok AS, et al. Hepatitis B Virus RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal. J Infect Dis. 2025. PMID: 39478672. doi:10.1093/infdis/jiae541

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。